Claudio Laudani, M.D.

Claudio Laudani M.D.

Courtesy - PDA

Department: Department of Medicine

Publications

2025
A Pairwise and Network Meta-analysis of Anti-inflammatory Strategies After Myocardial Infarction: the TITIAN study
European Heart Journal - Cardiovascular Pharmacotherapy.():-[DOI] 10.1093/ehjcvp/pvae100.[PMID] .
PubMed·Publisher's Site
2025
Changes in Coagulation Factor XI Activity Levels in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI.
Thrombosis and haemostasis.():-[DOI] 10.1055/a-2525-4219.[PMID] 39870112.
PubMed·Publisher's Site
2025
Completeness, timing, and guidance of percutaneous coronary intervention for myocardial infarction and multivessel disease: a systematic review and network meta-analysis.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.21(4):e203-e216[DOI] 10.4244/EIJ-D-24-00814.[PMID] 39962946.
PubMed·Publisher's Site
2025
Downstream cangrelor versus upstream ticagrelor in patients with ST-segment elevation myocardial infarction: A propensity score-matched analysis.
International journal of cardiology.418():132660-[DOI] 10.1016/j.ijcard.2024.132660.[PMID] 39428076.
PubMed·Publisher's Site
2025
Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects.
Circulation.151(6):400-415[DOI] 10.1161/CIRCULATIONAHA.124.069210.[PMID] 39928714.
1 citations·PubMed·Publisher's Site
2025
Sex-Related Differences in the Prognostic Role of Acetylcholine Provocation Testing.
Journal of the American Heart Association.14(5):e037942-[DOI] 10.1161/JAHA.124.037942.[PMID] 39996450.
PubMed·Publisher's Site
2024
Assessment of Noninferiority Margins in Cardiovascular Medicine Trials.
JACC. Advances.3(7):101021-[DOI] 10.1016/j.jacadv.2024.101021.[PMID] 39130003.
1 citations·PubMed·Publisher's Site
2024
Association of trial characteristics with simultaneous publication and its impact on citations and mentions: a cross-sectional study.
Revista espanola de cardiologia (English ed.).77(4):324-331[DOI] 10.1016/j.rec.2023.09.009.[PMID] 37848159.
2 citations·PubMed·Publisher's Site
2024
Characteristics and Impact of Randomized Trials on Drugs or Devices in Cardiovascular Medicine.
American journal of cardiovascular drugs : drugs, devices, and other interventions.24(5):651-661[DOI] 10.1007/s40256-024-00670-4.[PMID] 39088111.
PubMed·Publisher's Site
2024
Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis.
Circulation.149(14):1065-1086[DOI] 10.1161/CIRCULATIONAHA.123.067583.[PMID] 38344859.
17 citations·PubMed·Publisher's Site
2024
Exploring the impact of cardiologists expertise on publication metrics.
International journal of cardiology.406():132087-[DOI] 10.1016/j.ijcard.2024.132087.[PMID] 38648917.
PubMed·Publisher's Site
2024
Long-term impact of intravascular ultrasound-guidance for percutaneous coronary intervention on unprotected left main. The IMPACTUS-LM, an observational, multicentric study.
International journal of cardiology.401():131861-[DOI] 10.1016/j.ijcard.2024.131861.[PMID] 38365014.
2 citations·PubMed·Publisher's Site
2024
Older women with non-ST-elevation acute coronary syndrome undergoing invasive or conservative management: an individual patient data meta-analysis
European Heart Journal Open.4(6):-[DOI] 10.1093/ehjopen/oeae093.[PMID] 39698149.
PubMed·Publisher's Site
2024
P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis.
European heart journal. Cardiovascular pharmacotherapy.10(7):588-598[DOI] 10.1093/ehjcvp/pvae057.[PMID] 39054275.
3 citations·PubMed·Publisher's Site
2024
Percutaneous interventions for pulmonary embolism.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.20(7):e408-e424[DOI] 10.4244/EIJ-D-23-00895.[PMID] 38562073.
3 citations·PubMed·Publisher's Site
2024
Periprocedural myocardial infarction and injury.
European heart journal. Acute cardiovascular care.13(5):433-445[DOI] 10.1093/ehjacc/zuae014.[PMID] 38323856.
1 citations·PubMed·Publisher's Site
2024
Pharmacological and clinical appraisal of factor XI inhibitor drugs.
European heart journal. Cardiovascular pharmacotherapy.10(3):245-258[DOI] 10.1093/ehjcvp/pvae002.[PMID] 38196141.
6 citations·PubMed·Publisher's Site
2024
Response by Giacoppo et al to Letter Regarding Article "Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis".
Circulation.150(13):e271-e272[DOI] 10.1161/CIRCULATIONAHA.124.071021.[PMID] 39325501.
PubMed·Publisher's Site
2024
The pharmacology of antiplatelet agents for primary, secondary, and tertiary prevention of ischemic stroke.
Expert opinion on pharmacotherapy.25(10):1373-1390[DOI] 10.1080/14656566.2024.2385135.[PMID] 39046451.
PubMed·Publisher's Site
2024
Ticagrelor in Clopidogrel-Treated Patients With Chronic Coronary Syndrome Undergoing PCI: Translating Pharmacodynamic Into Clinical Evidence.
JACC. Cardiovascular interventions.17(12):1422-1424[DOI] 10.1016/j.jcin.2024.04.038.[PMID] 38842998.
PubMed·Publisher's Site
2023
A review of polypills for the prevention of atherosclerotic cardiovascular disease.
American heart journal.266():74-85[DOI] 10.1016/j.ahj.2023.08.012.[PMID] 37634656.
2 citations·PubMed·Publisher's Site
2023
Antithrombotic Management in AF Patients Following Percutaneous Coronary Intervention: A European Perspective.
Interventional cardiology (London, England).18():e05-[DOI] 10.15420/icr.2021.30.[PMID] 37601736.
4 citations·PubMed·Publisher's Site
2023
Antithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke: JACC State-of-the-Art Review.
Journal of the American College of Cardiology.82(15):1538-1557[DOI] 10.1016/j.jacc.2023.07.025.[PMID] 37793752.
12 citations·PubMed·Publisher's Site
2023
Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management.
Expert opinion on drug safety.22(12):1193-1212[DOI] 10.1080/14740338.2023.2291865.[PMID] 38048099.
2 citations·PubMed·Publisher's Site
2023
Complete Percutaneous Coronary Revascularization in Acute Coronary Syndromes With Multivessel Coronary Disease: A Systematic Review.
JACC. Cardiovascular interventions.16(19):2347-2364[DOI] 10.1016/j.jcin.2023.07.043.[PMID] 37821180.
15 citations·PubMed·Publisher's Site
2023
Diuresis-matched versus standard hydration in patients undergoing percutaneous cardiovascular procedures: meta-analysis of randomized clinical trials.
Revista espanola de cardiologia (English ed.).76(10):759-766[DOI] 10.1016/j.rec.2023.02.001.[PMID] 36801376.
1 citations·PubMed·Publisher's Site
2023
Eligibility to Intensified Antithrombotic Regimens for Secondary Prevention in Patients Who Underwent Percutaneous Coronary Intervention.
The American journal of cardiology.199():7-17[DOI] 10.1016/j.amjcard.2023.04.036.[PMID] 37216783.
5 citations·PubMed·Publisher's Site
2023
Impact of the ISCHEMIA trial on the role of noninvasive diagnostic pathways in patients with chronic coronary syndrome.
Journal of cardiovascular computed tomography.17(3):236-238[DOI] 10.1016/j.jcct.2023.03.005.[PMID] 36964097.
PubMed·Publisher's Site
2023
Pharmacology and Clinical Development of Factor XI Inhibitors.
Circulation.147(11):897-913[DOI] 10.1161/CIRCULATIONAHA.122.062353.[PMID] 36913497.
40 citations·PubMed·Publisher's Site
2023
Unraveling the Maze of De-Escalation Strategies in Acute Coronary Syndromes.
Circulation. Cardiovascular interventions.16(9):e013461-[DOI] 10.1161/CIRCINTERVENTIONS.123.013461.[PMID] 37609847.
1 citations·PubMed·Publisher's Site
2022
Culprit Lesions Phenotypes in ST-Segment Elevation Acute Coronary Syndromes: A Call for Precision Medicine.
JACC. Cardiovascular interventions.15(8):857-860[DOI] 10.1016/j.jcin.2022.02.037.[PMID] 35367171.
PubMed·Publisher's Site
2022
Reply: Short Duration of DAPT vs De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes.
JACC. Cardiovascular interventions.15(9):999-1000[DOI] 10.1016/j.jcin.2022.03.030.[PMID] 35512924.
PubMed·Publisher's Site
2022
Reply: Short Duration of DAPT vs De-Escalation After Percutaneous Coronary Intervention: Only These 2 Options?
JACC. Cardiovascular interventions.15(8):903-904[DOI] 10.1016/j.jcin.2022.03.007.[PMID] 35450693.
PubMed·Publisher's Site
2022
Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes.
JACC. Cardiovascular interventions.15(3):268-277[DOI] 10.1016/j.jcin.2021.11.028.[PMID] 35144783.
65 citations·PubMed·Publisher's Site